Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Haloperidol Decanoate

FDA-approved product (injectable, injection), marketed as Haldol, Haloperidol Decanoate.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Haloperidol Decanoate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Conduct disorder
  • Mental or behavioural disorder
  • Psychosis
  • Schizoaffective disorder
  • Schizophrenia
  • Tics
  • Tourette syndrome

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Butyrophenone derivatives
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA55.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli51.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae29.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis70.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Haloperidol Decanoate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Haloperidol Decanoate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Oral Olanzapine Versus Haloperidol or Diazepam

    NCT03246620 · start 2017-09-01

    Registered record
    Registry ID
    NCT03246620
    Conditions
    Acute Agitation; Behavioural Emergency
    Interventions
    Olanzapine oro-dispersible 5Mg Tab; Haloperidol 2Mg encapsulated Tab; Diazepam 2Mg encapsulated Tab
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2017-09-01
    Completion
    2018-06-01
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Agitation; Behavioural Emergency
    InterventionOlanzapine oro-dispersible 5Mg Tab; Haloperidol 2Mg encapsulated Tab; Diazepam 2Mg encapsulated Tab
    PhasePhase 4
    Registry statusTerminated

  • Olanzapine, Haloperidol, Ziprasidone, Midazolam for Acute Undifferentiated Agitation

    NCT03211897 · start 2017-06-15

    Registered record
    Registry ID
    NCT03211897
    Conditions
    Agitation,Psychomotor
    Interventions
    Haloperidol Injection; Ziprasidone Injection; OLANZapine Injection; Midazolam injection
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2017-06-15
    Completion
    2017-10-01
    Enrolment
    737

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAgitation,Psychomotor
    InterventionHaloperidol Injection; Ziprasidone Injection; OLANZapine Injection; Midazolam injection
    PhaseNot recorded
    Registry statusCompleted

  • Pharmacological Modulation of Belief Salience

    NCT03754062 · start 2017-06-01

    Registered record
    Registry ID
    NCT03754062
    Conditions
    Haloperidol; Placebo; L-DOPA
    Interventions
    Placebo - Cap; L-dopa; Haloperidol
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2017-06-01
    Completion
    2019-09-01
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHaloperidol; Placebo; L-DOPA
    InterventionPlacebo - Cap; L-dopa; Haloperidol
    PhasePhase 1
    Registry statusCompleted

  • Real-time Decision Support for Postoperative Nausea and Vomiting (PONV) Prophylaxis

    NCT02625181 · start 2016-07

    Registered record
    Registry ID
    NCT02625181
    Conditions
    Postoperative Nausea and Vomiting
    Interventions
    Automated recommendation at the start of the case; Automated notification at the start of surgery; Preoperative recommendations: by email; Automated notification at the end of surgery; Anesthesia Information Management System (AIMS); Perioperative Data Warehouse (PDW); General anesthesia; Elective surgery; Propofol; Sevoflurane; Isoflurane; Desflurane; Scopolamine; Droperidol; Haloperidol; Dexamethasone; Promethazine; Meclizine; Aprepitant; Metoclopramide; Fentanyl; Sufentanil; Alfentanil; Remifentanil; Morphine; Meperidine; Hydromorphone; Methadone; Oxycodone; Oxymorphone; Hydrocodone; Ketamine; Ondansetron; Granisetron; Dolasetron mesylate; Palonosetron; Tropisetron; Ramosetron
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2016-07
    Completion
    2017-11-30
    Enrolment
    27,034

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPostoperative Nausea and Vomiting
    InterventionAutomated recommendation at the start of the case; Automated notification at the start of surgery; Preoperative recommendations: by email; Automated notification at the end of surgery +34 more
    PhaseNot applicable
    Registry statusCompleted

  • Treatment of Hypoactive Delirium and Outcome Measures

    NCT02345902 · start 2016-01

    Registered record
    Registry ID
    NCT02345902
    Conditions
    Hypoactive Delirium
    Interventions
    Haloperidol; Placebo; non-pharmacologic measures
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2016-01
    Completion
    2018-12
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypoactive Delirium
    InterventionHaloperidol; Placebo; non-pharmacologic measures
    PhasePhase 3
    Registry statusUnknown

  • Evaluation of the Necessity of Long-term Pharmacological Treatment With Antipsychotics in Schizophrenic Patients

    NCT02307396 · start 2015-02-01

    Registered record
    Registry ID
    NCT02307396
    Conditions
    Schizophrenia; Schizophrenia and Disorders With Psychotic Features; Schizoaffective Disorders
    Interventions
    Olanzapine; Amisulpride; Risperidone; Haloperidol; Quetiapine; Perphenazine; Sulpiride; bromperidol; Zuclopenthixol; Thioridazine; Paliperidone; Ziprasidone; Benperidol; Fluspirilene; Pimozide; Perazine; Fluphenazine; Flupentixole; Sertindole
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2015-02-01
    Completion
    2016-06-22
    Enrolment
    21

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia; Schizophrenia and Disorders With Psychotic Features; Schizoaffective Disorders
    InterventionOlanzapine; Amisulpride; Risperidone; Haloperidol +15 more
    PhasePhase 4
    Registry statusCompleted

  • Valproic Acid for Treatment of Hyperactive or Mixed Delirium in ICU

    NCT02343575 · start 2015-01

    Registered record
    Registry ID
    NCT02343575
    Conditions
    Hyperactive Delirium; Mixed Delirium
    Interventions
    Valproic Acid; Placebo; Haloperidol
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2015-01
    Completion
    2018-01
    Enrolment
    3

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHyperactive Delirium; Mixed Delirium
    InterventionValproic Acid; Placebo; Haloperidol
    PhasePhase 4
    Registry statusTerminated

  • A Concierge Model of CAE Plus LAI in Individuals With Schizophrenia at Risk for Treatment Non-adherence and Homelessness

    NCT02085447 · start 2014-05

    Registered record
    Registry ID
    NCT02085447
    Conditions
    Psychotic Disorders; Schizophrenia; Schizoaffective Disorder; Medication Adherence; Medication Non-Adherence
    Interventions
    CAE-L
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2014-05
    Completion
    2016-12
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPsychotic Disorders; Schizophrenia; Schizoaffective Disorder; Medication Adherence +1 more
    InterventionCAE-L
    PhaseNot applicable
    Registry statusCompleted

  • Non-sedation Versus Sedation With a Daily Wake-up Trial in Critically Ill Patients Receiving Mechanical Ventilation - Effects on Physical Function

    NCT02034942 · start 2014-01

    Registered record
    Registry ID
    NCT02034942
    Conditions
    Critically Ill; Muscular Atrophy
    Interventions
    Non-sedation; Sedation, control
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2014-01
    Completion
    2019-03
    Enrolment
    205

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCritically Ill; Muscular Atrophy
    InterventionNon-sedation; Sedation, control
    PhaseNot applicable
    Registry statusCompleted

  • Neuroendocrine and Metabolite Substrates in Schizophrenia

    NCT02423096 · start 2013-12

    Registered record
    Registry ID
    NCT02423096
    Conditions
    Schizophrenia
    Interventions
    Risperidone
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2013-12
    Completion
    2016-12
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionRisperidone
    PhaseNot recorded
    Registry statusUnknown

  • Randomized Trial of the Effectiveness of Topical "ABH Gel" vs. Placebo in Cancer Patients With Nausea

    NCT01556932 · start 2012-03

    Registered record
    Registry ID
    NCT01556932
    Conditions
    Nausea; Vomiting
    Interventions
    ABH gel; placebo
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2012-03
    Completion
    2014-05
    Enrolment
    22

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNausea; Vomiting
    InterventionABH gel; placebo
    PhaseNot applicable
    Registry statusCompleted

  • Optimal Haloperidol Dose for Postoperative Nausea and Vomiting Prevention in High-risk Patients

    NCT01639599 · start 2012-03

    Registered record
    Registry ID
    NCT01639599
    Conditions
    Gynecological Disease
    Interventions
    Dexamethasone iv injection; Dexamethasone, haloperidol; Dexamethasone, haloperidol
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2012-03
    Completion
    2013-05
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGynecological Disease
    InterventionDexamethasone iv injection; Dexamethasone, haloperidol; Dexamethasone, haloperidol
    PhaseNot applicable
    Registry statusCompleted

  • Incidence of Chemotherapy-Induced Nausea and Vomiting Associated With Docetaxel-Cyclophosphamide in Early Breast Cancer.

    NCT01298193 · start 2011-05

    Registered record
    Registry ID
    NCT01298193
    Conditions
    Breast Cancer
    Interventions
    Aprepitant
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2011-05
    Completion
    2014-04
    Enrolment
    212

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    InterventionAprepitant
    PhasePhase 4
    Registry statusCompleted

  • A Comparison of Long-acting Injectable Medications for Schizophrenia

    NCT01136772 · start 2011-03

    Registered record
    Registry ID
    NCT01136772
    Conditions
    Schizophrenia; Schizoaffective Disorder
    Interventions
    haloperidol decanoate; paliperidone palmitate
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2011-03
    Completion
    2016-07
    Enrolment
    311

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia; Schizoaffective Disorder
    Interventionhaloperidol decanoate; paliperidone palmitate
    PhasePhase 4
    Registry statusCompleted

  • Evaluation of Delirium Prevention in Critically Ill Patients

    NCT01187667 · start 2010-08

    Registered record
    Registry ID
    NCT01187667
    Conditions
    Delirium
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2010-08
    Completion
    2011-10
    Enrolment
    650

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDelirium
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted